Evidence map›Paper›PMID 40522093›Full record

ArticleMicrobiology spectrum2025

The human gut microbiome and its metabolic pathway dynamics before and during HIV antiretroviral therapy.

Oumar Dolo, Fousseini Coulibaly, Anou M Somboro, Shan Sun, Modibo Diarra, Aminata Maiga, Soungou Bore, Djeneba B Fofana, Anne-Genevieve Marcelin, Brehima Diakite and 8 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Oumar Dolo *University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.ORCID 0009-0003-4401-0710
Fousseini Coulibaly *Medical Biology Laboratory of the Point G University Hospital Center, Bamako, Bamako Capital District, Mali.
Anou M SomboroUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.ORCID 0000-0002-1085-7740
Shan SunDepartment of Bioinformatics, University of North Carolina at Charlotte, Charlotte, North Carolina, USA.
Modibo DiarraResearch and Training Center for Molecular Pathologies (CREFPAM), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.
Aminata MaigaMedical Biology Laboratory of the Point G University Hospital Center, Bamako, Bamako Capital District, Mali.
Soungou BoreResearch and Training Center for Molecular Pathologies (CREFPAM), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.
Djeneba B FofanaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.
Anne-Genevieve MarcelinVirology Department of the "Pitié-Salpêtrière" Hospital, Paris, France.
Brehima DiakiteResearch and Training Center for Molecular Pathologies (CREFPAM), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.
Yaya KassogueResearch and Training Center for Molecular Pathologies (CREFPAM), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.
Jane L HollDepartment of Neurology, University of Chicago, Chicago, Illinois, USA.
Vincent CalvezVirology Department of the "Pitié-Salpêtrière" Hospital, Paris, France.
Cheick B TraoréResearch and Training Center for Molecular Pathologies (CREFPAM), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.
Robert MurphyInstitute for Global Health, Northwestern University, Evanston, Illinois, USA.
Anthony A FodorDepartment of Bioinformatics, University of North Carolina at Charlotte, Charlotte, North Carolina, USA.
Mamoudou MaigaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.ORCID 0000-0001-7871-3973
Almoustapha I MaigaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako, Bamako, Bamako Capital District, Mali.ORCID 0000-0001-7675-4915

Funding

Northwestern University Clinical Trial UnitUM1AI069471 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Chad J Achenbach · 2012 to 2026
$24.6M
The Center for Innovation in Point-of-Care Technologies for HIV/AIDS atNorthwestern University (C-THAN) Supplemental RequestU54EB027049 · NIBIB · NORTHWESTERN UNIVERSITY · PI Kara M Palamountain · 2018 to 2026
$24.0M
Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
West Africa Self-Sampling HPV Based Cervical Cancer Control Program (WA-SS-HCCP) for WLWHA: Barriers, challenges, and needsU01CA275129 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JANE Louise HOLL, Lifang Hou · 2022 to 2026
$3.2M
HIV and Mycobacterial Disease in MaliD43TW010350 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI MAIGA, ALMOUSTAPHA ISSIAKA, MURPHY, ROBERT LEO · 2016 to 2025
$3.0M
Infection-Associated Cancer Research Training Program in MaliD43CA260658 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HOU, LIFANG, MAIGA, MAMOUDOU · 2021 to 2025
$1.3M
Metabolic and Immune Consequences of Antibiotic-Related Microbiome Alterations during TB TreatmentR21AI148033 · NIAID · NORTHWESTERN UNIVERSITY · PI MAIGA, MAMOUDOU · 2019 to 2020
$440k
FIC NIH HHS D43 TW010350FIC NIH HHS D43 TW010543NCI NIH HHS D43 CA260658NCI NIH HHS U01 CA275129NIAID NIH HHS R21 AI148033NIAID NIH HHS UM1 AI069471NIBIB NIH HHS U54 EB027049
6 · The paper itself

Abstract

The human gut microbiome consists of highly complex microbial populations that play important roles in disease pathogenesis. Changes in the gut microbiome are associated with HIV infection. However, it is unclear whether gut microbiome dysbiosis is causally linked to disease or whether it simply reflects disease-induced changes in the host immune and metabolic systems. This study aims to describe and compare intestinal microbial compositions and derived metabolic pathways in people living with HIV (PL-HIV) from prior to antiretroviral therapy (ART) to 6 and 12 months after ART initiation, compared to HIV-negative individuals. Whole-genome microbiome sequencing coupled with bioinformatics analysis was used to characterize participants' intestinal microbial structures and derived metabolic pathways. Pre- and post-ART gut microbiota characterization of PL-HIV revealed substantial dysbiosis compared to HIV-negative people. An enrichment of pro-inflammatory microorganisms was the hallmark of dysbiosis in the PL-HIV pre-ART, with a decline in

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsBacteriaDysbiosisGastrointestinal MicrobiomeHIV InfectionsMetabolic Networks and PathwaysAdultFecesFemaleHumansMaleMiddle AgedWhole Genome SequencingAnti-HIV AgentsAnti-Retroviral Agentsantiretroviral therapygut microbiotaHIVMali

Identifiers

PMID40522093
PMCPMC12323315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.